TG-C [TissueGene-C] is a first-in-class cell-mediated gene therapy targeting osteoarthritis (OA) of the knee through a single intra-articular injection. Clinical trials held in the United States and abroad have demonstrated pain relief and increased mobility, as well indicators towards decreased progression of OA and improvements in joint structure. The allogeneic cell therapy product could provide an alternative to traditional treatment and surgery, or delay the progression of OA to minimize the need for multiple surgical interventions. The TG-C cell therapy product is being developed in two dosages: TG-C developed in the United States by Kolon TissueGene and TG-C LD developed in Korea by Kolon Life Science.